Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Sponsor: Wuxi Hisky Medical Technology Co Ltd
Summary
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.
Official title: Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
2900
Start Date
2022-07-01
Completion Date
2027-06-01
Last Updated
2022-10-28
Healthy Volunteers
No
Interventions
Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination
Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
Locations (1)
Zhongda Hospital, Medical School, Southeast University
Nanjing, Jiangsu, China